Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shayan Khorsandi

Urogynecology and Reconstructive Pelvic Surgery Vega Baja, PR Medical Doctor

NPI 1083159305 CMS profile 5417370

Carr # 2 Km 39.5, Vega Baja, PR 00693

Open in the dashboard

General payments

$12,518

40 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shayan Khorsandi of Vega Baja, PR is reported in the CMS Open Payments database as having received $12,518 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $367 9
2024 General $352 8
2023 General $257 4
2022 General $1,285 6
2020 General $10,090 3
2019 General $166 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shayan Khorsandi
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Shayan Khorsandi were reported at $367. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Shayan Khorsandi Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $166 $358 $132–$1,270 $163
2020 $10,090 $198 $86–$642 $114
2021 $0 $361 $118–$1,182 $132
2022 $1,285 $410 $128–$1,175 $149
2023 $257 $434 $152–$1,344 $160
2024 $352 $494 $193–$1,331 $164
2025 $367 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $10,000 1 payment
  2. Boston Scientific Corporation $1,530 10 payments
  3. Medtronic, Inc. $408 13 payments
  4. AbbVie, Inc. $157 7 payments
  5. Roche Diagnostics Corporation $125 1 payment
  6. Axonics Modulation Technologies, Inc. $95 1 payment
  7. Johnson and Johnson International $89 1 payment
  8. Avanos Medical $56 2 payments
  9. GlaxoSmithKline, LLC. $29 2 payments
  10. TherapeuticsMD, Inc. $15 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $10,000 1 payment
  2. Food and Beverage $1,465 34 payments
  3. Travel and Lodging $1,039 4 payments
  4. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. INTERSTIM Sacral Nerve Stimulation $10,000 1 payment
  2. Solyx SIS System $1,285 6 payments
  3. INTERSTIM Sacral Nerve Stimulation $408 13 payments
  4. Advantage System $146 1 payment
  5. cobas 4800 CT/NG Test v2.0 $125 1 payment
  6. Axonics $95 1 payment
  7. ORILISSA $90 2 payments
  8. SURGICEL NU-KNIT $89 1 payment
  9. Harmonic $89 1 payment
  10. Echelon Flex $89 1 payment
  11. Other $397 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

1,116

Median for Obstetrics & Gynecology: 65

Drug cost

$81,729

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

30%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 114 $56,168
Estradiol Generic 127 $11,289
Trospium Chloride Generic 113 $6,359
Methenamine Hippurate Generic 28 $1,847
Gabapentin Generic 151 $986
Clobetasol Propionate Generic 45 $968
Ibuprofen Generic 181 $941
Acetaminophen-Codeine Acetaminophen With Codeine Brand 112 $869
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 42 $842
Cephalexin Generic 136 $760

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record